oral CNS-penetrant Nav1.7/1.8 blocker

in vivo efficacy in rodent pain models

electrophysiology-based HTS and opt.

Bioorg. Med. Chem.

AbbVie, North Chicago, IL

ABBV-318, oral CNS-penetrant Nav1.7/1.8 blocker - AbbVie, North Chicago, IL

Context. ABBV-318 (AbbVie) is a CNS-penetrating, oral inhibitor of Nav1.7/Nav1.8 being developed for pain treatment. Despite being a highly validated pain target due to its important role in excitable…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: